Drug Trial Radar · NCT00384085
Insulin Glargine "All to Target" Trial
Last checked: Nov 20, 2026Latest source record: May 6, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
588
Actual
Start
May 2006
Primary completion
Mar 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives were: * To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic control (as measured by hemoglobin A1c \[HbA1c\] \<7.0%) at Week 60 * To demonstrate the noninferiority of Lantus plus addition of 1 mealtime Apidra injection (Lantus/Apidra-1) versus twice-daily Premixed insulin based on the reduction from Baseline to Week 60 in HbA1c
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin GlulisineDrug
Subcutaneous injection up to 1 injection per day
Insulin GlargineDrug
Subcutaneous injection once-a-day
Premixed InsulinDrug
Subcutaneous injection twice-a-day.
Insulin GlulisineDrug
Subcutaneous injection up to 3 injections per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)Time frame: At week 60
- Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol PopulationTime frame: At week 60
- Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)Time frame: At week 60
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.